Overview

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-26

Target enrollment:

Participant gender:

Summary

This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with simmitinib; Cohort 2 includes dose escalation/dose extension of DP303c combined with irinotecan liposomes, as well as RCT stage of DP303c combined with irinotecan liposomes.

Phase:

PHASE1

Details

Lead Sponsor:

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Treatments:

Docetaxel
Irinotecan
Paclitaxel